I agree X,It does sound like all you describe and that's a...

I agree X,
It does sound like all you describe and that's a decision each investor must make.
I use the patches along with my aging family and our quality of life has improved as a result.
My wife takes opiates to manage pain which do not do enough. She now uses the patches and while they do not cure her pain, they make her 100% better to live with, her pain is now manageable. For what it's worth I have a pharmacological background and worked with Pfizer as a specialist drug rep selling pain relief medication amongst others. For the individuals that I know, this patch has worked the best so far out of all the things I have had them try. For me Reduit was a hit or miss product from the start. If Reduit is all we had, no way would I invest further.
The patch will sell because it works. Of course, not everyone will feel benefit however my personal feeling is that the majority will. As an example, the two people I suggested to try the patches that had ongoing pain after knee replacement surgery saw no benefit. Thats 100% fail in that circumstance. All the others with pain to differing joints saw benefit ranging from a young age of 16 to 78 years old. Provided our company survives this cash flow issue I feel that finally the investment I made will come to be realized. For what it's worth I have been invested since the 3M rumor announcements many years ago. When the bodyguard results were posted I felt that product was the one needed for this companies' success. I have been waiting ever since and finally the year has arrived that will determine my fate.
The patch is not a gimmick and meets a need that unfortunately will always be. This is why this product is different. It's the fact that our technology can transport substances already proven to be effective in pain relief, to the immediate site required without being metabolized and therefore their effectiveness diminished, that makes it unique and work better. Yes, I am a shareholder and yes, I want to make money and yes, in my humble opinion I feel we will do well with Swisswell, and finally yes, I wish that all existing shareholders that can afford to support the CR, do so.

Spatch